The Art (and Blood Sport) of Psychopharmacology Research: Who Has a Dog in the Fight?

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text. We wish to highlight 2 Letters to the Editor that appear in this issue. Gharabawi et al. provide commentary on an article published in The Journal of Clinical Psychiatry by Zhong et al. (2006).¹ All of the authors of this letter are employed by companies that have a financial interest in the sales of risperidone. The reply is provided by several of the authors of the article published in the Journal, with the particular authors of the response letter (Sweitzer et al.) being employees of another pharmaceutical company, one that sells quetiapine.